|
|
Home > Health
Conditions > Ejection fraction
Ejection fraction
Alternative News:
-
Effects of Ubiquinol and/or
D-ribose in Patients With Heart Failure With Preserved Ejection Fraction -
Am J Cardiol 2022 May 26 - "Patients with heart failure
with preserved ejection fraction (HFpEF) have few pharmacologic therapies, and
it is not known if supplementing with ubiquinol and/or d-ribose could improve
outcomes ... Group 1 received placebo ubiquinol capsules and d-ribose powder,
Group 2 received ubiquinol capsules (600 mg/d) and placebo d-ribose powder,
Group 3 received placebo ubiquinol capsules with d-ribose powder (15 g/d), and
Group 4 received ubiquinol capsules and d-ribose powder ... Kansas City
Cardiomyopathy Questionnaire (KCCQ) clinical summary score ... Treatment with
ubiquinol and/or d-ribose significantly improved the KCCQ clinical summary score
(17.30 to 25.82 points), vigor score (7.65 to 8.15 points), and EF (7.08% to
8.03%) and reduced B-type natriuretic peptides (-72.02 to -47.51) and
lactate/adenosine triphosphate ratio (-4.32 to -3.35 × 10-4). There were no
significant increases in the septal E/e' or the 6-minute walk test. In
conclusion, ubiquinol and d-ribose reduced the symptoms of HFpEF and increased
the EF. These findings support the use of these supplements in addition to
standard therapeutic treatments for patients with HFpEF" - See
ubiquinol products at Amazon.com and
D-ribose at Amazon.com.
-
Effects of Sacubitril/Valsartan
on clinical symptoms, echocardiographic parameters, and outcomes in HFrEF and
HFmrEF patients with coronary heart disease and chronic kidney disease -
Curr Med Res Opin 2021 Mar 25 - "To compare the effects
of Angiotensin Receptor-Neprilysin inhibitor (ARNI) on the clinical symptoms,
echocardiographic parameters, and outcomes (cardiovascular death and
hospitalization) in heart failure with reduced ejection fraction (HFrEF) and
heart failure with mid-range ejection fraction (HFmrEF) patients with coronary
heart disease and chronic kidney disease ... A statistically significant
increase of 68.8% was observed in left ventricular ejection fraction (LVEF) in
HFrEF patients compared to that in HFmrEF patients, with an increase of 27.2% at
8 months of follow-up. Sacubitril/valsartan significantly reduced left
ventricular end-systolic volumes (LVESV) in HFrEF patients unlike in HFmrEF
patients. The decrease in LVESV was 28.8% in HFrEF patients and 17.1% in HFmrEF
patients. A significant reduction in the prevalence of severe secondary mitral
regurgitation (EROA >0.4cm2) was observed in HFrEF compared to that in HFmrEF
patients with the use of sacubitril/valsartan. A reduction of 15.6% was observed
in HFrEF patients, whereas a reduction of 7.1% was observed in HFmrEF patients.
Improvement in functional classification (NYHA) was observed during follow-up.
The prevalence of (NYHA III) reduced from 50% to 15.7% in HFrEF patients,
whereas a reduction from 21.1% to 8.8% was observed in HFmrEF patients. There
was a significant reduction in NT-proBNP in HFrEF patients compared to that in
HFmrEF patients. A reduction of 52% was observed in HFrEF patients, whereas a
reduction of 28.7% was observed in HFmrEF pateints. Sacubitril/valsartan reduced
primary endpoint events in both groups. The prevalence of HF-related
hospitalization was higher in HFrEF than in HFmrEF patients: 12.1% vs 7.5%,
respectively. The prevalence of CV death in HFrEF vs HFmrEF patients was 3.7% vs
0.5%, respectively. Cardiovascular (CV) was higher in patients with atrial
fibrillation in both groups"
-
Randomized Trial of
Empagliflozin in Nondiabetic Patients With Heart Failure and Reduced Ejection
Fraction - J Am Coll Cardiol 2021 Jan 26 -
"Empagliflozin was associated with a significant reduction of LV end-diastolic
volume (-25.1 ± 26.0 ml vs. -1.5 ± 25.4 ml for empagliflozin vs. placebo,
respectively; p < 0.001) and LV end-systolic volume (-26.6 ± 20.5 ml vs. -0.5 ±
21.9 ml for empagliflozin vs. placebo; p < 0.001). Empagliflozin was associated
with reductions in LV mass (-17.8 ± 31.9 g vs. 4.1 ± 13.4 g, for empagliflozin
vs. placebo, respectively; p < 0.001) and LV sphericity, and improvements in LV
ejection fraction (6.0 ± 4.2 vs. -0.1 ± 3.9; p < 0.001). Patients who received
empagliflozin had significant improvements in peak O2 consumption (1.1 ± 2.6
ml/min/kg vs. -0.5 ± 1.9 ml/min/kg for empagliflozin vs. placebo, respectively;
p = 0.017), oxygen uptake efficiency slope (111 ± 267 vs. -145 ± 318; p <
0.001), as well as in 6-min walk test (81 ± 64 m vs. -35 ± 68 m; p < 0.001) and
quality of life (Kansas City Cardiomyopathy Questionnaire-12: 21" - See
empagliflozin inhousepharmacy.vu.
-
Tolerability and efficacy
of Sacubitril/ Valsartan in clinical practice - Intern Med J. 2020 Jan 6 -
"Heart failure is a major cause of morbidity and
mortality. Sacubitril/Valsartan has demonstrated reductions in HF
hospitalisation, and all-cause mortality in patients with heart failure with
reduced ejection fraction (HFrEF) ... 14% of patients were able to able to
achieve maximal dose (97/103 mg twice daily) whilst 37% remained on 49/51 mg and
23% on 24/26 mg. The mean SBP reduced from 118 ± 18 mmHg to 109 ± 15 mmHg with
symptomatic hypotension (30%) being the most common side effect leading to dose
reduction or drug cessation. Left ventricular ejection fraction (LVEF) improved
from 29.1 ± 9.7% to 33.8 ± 9.9% (p < 0.05) on drug. There was also a significant
improvement in quality of life scores; EQ5D-VAS 40 pre vs 67 post Sacubitril/Valsartan
(p < 0.05), and New York Heart Association class (p < 0.05). Importantly, ten
patients lost an existing indication for device based therapy after treatment
with Sacubitril/Valsartan ... Sacubitril/Valsartan is a much needed therapeutic
advancement in the treatment of HF. Our study indicates it is well tolerated
with improvements in cardiac function and symptoms. Sacubitril/Valsartan could
redefine the definition of "optimal medical therapy' when assessing patients for
device based therapies"
-
Combination therapy using
tafamidis and neurohormonal blockers for cardiac amyloidosis and a reduced
ejection fraction: a case report - J Int Med Res 2022 Jul -
"We report a 77-year-old man who was diagnosed with wild-type cardiac
amyloidosis and systolic dysfunction with a left ventricular ejection fraction
of 27%. Following 6-month medical therapy of tafamidis 80 mg and neurohormonal
blockers (carvedilol 5.0 mg, enalapril 2.5 mg, and spironolactone 25 mg), the
left ventricular ejection fraction improved to 55%. Tafamidis-incorporated
neurohormonal blocker therapy might be a promising strategy to facilitate
cardiac reverse remodeling in patients with cardiac amyloidosis and systolic
dysfunction"
-
Pfizer's blockbuster-to-be Vyndaqel is too costly for heart patients, study
suggests - fiercepharma.com, 6/19/20 - "Pfizer’s
tafamidis arrived in the U.S. in 2019 with a vastly discounted list price
over rival transthyretin amyloidosis drugs. But its $225,000-a-year tag
still seems too much for many heart patients"
Other News:
|
|